Literature DB >> 17680337

Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder.

Barbara Santarosa Emo Peters1, Rosa Maria Affonso Moyses, Vanda Jorgetti, Lígia Araújo Martini.   

Abstract

BACKGROUND/AIMS: Chronic renal failure (CRF) is often associated with bone disorders including chronic kidney disease-mineral and bone disorder (CKD-MBD). Parathyroid hormone (PTH) has a relationship to bone remodeling, and so this study was undertaken to evaluate changes in bone remodeling markers after parathyroidectomy (PTX).
METHODS: Twelve adult patients, mean age 43.4 +/- 12.7 years, of both genders, were evaluated, prior to and six months after PTX. Analysis of biochemical markers of bone metabolism, such as total and ionized calcium, phosphorus, 25(OH)D(3), total alkaline phosphatase (TAP), bone-specific alkaline phosphatase (BAP), intact PTH, osteoprotegerin (OPG), and tartrate-resistant acid phosphatase isoform 5b (TRAP), were measured.
RESULTS: No changes were observed after PTX in the serum total and ionized calcium, TAP, BAP, and 25(OH)D(3). After surgery there was a significant decrease in serum phosphorus, iPTH, and TRAP (P < 0.001). No significant change was observed in OPG; however there was a positive correlation between OPG and 25(OH)D(3) before and after surgery (r = 0.774, P = 0.014; and r = 0.706, P = 0.01, respectively). The percentage of patients with vitamin D deficiency decreased from 16.7% to 8.3%, while those with sufficient levels increased from 41.7% to 58.3%.
CONCLUSION: The small number of patients in the study notwithstanding, the present study is unique because it provides information on bone metabolism and vitamin D status six months after PTX. The removal of parathyroid glands significantly decreased bone resorption and indicated a tendency of 25(OH)D(3) concentration to increase. However, the precise role of OPG and BAP in the improvement in bone remodeling in patients with CKD-MBD requires further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680337     DOI: 10.1007/s11255-007-9254-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  Hyperphosphataemia--a silent killer of patients with renal failure?

Authors:  K Amann; M L Gross; G M London; E Ritz
Journal:  Nephrol Dial Transplant       Date:  1999-09       Impact factor: 5.992

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States.

Authors:  Robert E LaClair; Richard N Hellman; Sharon L Karp; Michael Kraus; Susan Ofner; Qian Li; Karen L Graves; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2005-06       Impact factor: 8.860

Review 5.  Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease.

Authors:  Michael F Holick
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

6.  Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.

Authors:  E López Gavilanes; E González Parra; C de la Piedra; C Caramelo; A Rapado
Journal:  Miner Electrolyte Metab       Date:  1994

7.  Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.

Authors:  L Scarnecchia; S Minisola; M T Pacitti; V Carnevale; E Romagnoli; R Rosso; G F Mazzuoli
Journal:  Scand J Clin Lab Invest       Date:  1991-10       Impact factor: 1.713

8.  Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.

Authors:  Misako Ueda; Masaaki Inaba; Senji Okuno; Kyoko Nagasue; Kayoko Kitatani; Eiji Ishimura; Motokazu Shimizu; Takami Miki; Masao Kim; Yoshiki Nishizawa
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

9.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.

Authors:  G G Schwartz; L W Whitlatch; T C Chen; B L Lokeshwar; M F Holick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-05       Impact factor: 4.254

10.  Parathyroidectomy: whom and when?

Authors:  Rosa Jofré; Juan Manuel López Gómez; Javier Menárguez; José Ramón Polo; Martin Guinsburg; Teresa Villaverde; Isabel Pérez Flores; Diana Carretero; Patrocinio Rodríguez Benitez; Rafael Pérez García
Journal:  Kidney Int Suppl       Date:  2003-06       Impact factor: 10.545

View more
  7 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Unusually prolonged vitamin D intoxication after discontinuation of vitamin D: possible role of primary hyperparathyroidism.

Authors:  Hulya Taskapan; Reinhold Vieth; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2008-06-05       Impact factor: 2.370

3.  Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism.

Authors:  Flavia Ramos de Siqueira; Karin Carneiro de Oliveira; Wagner Vasques Dominguez; César Augusto Madid Truyts; Rosa Maria Affonso Moysés; Luciene Machado Dos Reis; Vanda Jorgetti
Journal:  Eur J Clin Nutr       Date:  2021-01-18       Impact factor: 4.016

4.  Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations.

Authors:  Josée Bouchard; Denis Ouimet; Michel Vallée; Jean-Philippe Lafrance; Martine Leblanc; Lyne Sénécal; Alain Bonnardeaux; Jean-Pierre Mathieu; Vincent Pichette
Journal:  Int Urol Nephrol       Date:  2008-12-05       Impact factor: 2.370

5.  Serum fibroblast growth factor-23 levels in chronic haemodialysis patients.

Authors:  Salwa Ibrahim; Laila Rashed
Journal:  Int Urol Nephrol       Date:  2008-10-07       Impact factor: 2.370

6.  Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats.

Authors:  Li-Hua Ni; Ri-Ning Tang; Cheng Yuan; Kai-Yun Song; Li-Ting Wang; Xiao-Liang Zhang; Lin-Li Lv; Bin Wang; Min Wu; Tao-Tao Tang; Zuo-Lin Li; Di Yin; Jing-Yuan Cao; Xiao-Chen Wang; Hong Liu; Qiang Chen; Bi-Cheng Liu
Journal:  Ann Transl Med       Date:  2019-07

7.  Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

Authors:  João M Frazão; Johann Braun; Piergiorgio Messa; Bastian Dehmel; Caroline Mattin; Martin Wilkie
Journal:  BMC Nephrol       Date:  2012-08-03       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.